This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Biotech ETFs to Shine on Pfizer's Coronavirus Vaccine Progress
by Sweta Jaiswal, FRM
Two out of four of Pfizer's coronavirus vaccine candidates, BNT162b1 and BNT162b2, have been granted the 'fast track' designation by the FDA.
Biotech ETF (IBB) Hits a New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
3 Hot Sector ETFs to Tide Over the Coronavirus Crisis in Q3
by Sweta Jaiswal, FRM
Here we highlight three sectors that are sizzling with investing opportunities as the second wave of the outbreak is gathering steam.
Biotech ETFs to Gain as Coronavirus Vaccine Hopes Strengthen
by Sweta Jaiswal, FRM
As the coronavirus outbreak continues to aggravate, investors are eyeing developments in vaccine or treatments to combat the pandemic.
ETF Areas for July as Second Wave of Coronavirus Hits Hard
by Sweta Jaiswal, FRM
As the COVID-19 outbreak continues to aggravate in the United States, we discuss some ETF areas that investors can consider for investing in July.
Try These ETF Areas in Virus-Impacted Second Half of 2020
by Sweta Jaiswal, FRM
Here we highlight a few ETF areas that have the potential to do well in the second half of this year amid the coronavirus crisis.
Should You Invest in the Invesco Dynamic Biotechnology Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Moderna a Step Closer to Coronavirus Vaccine: ETFs to Gain
by Sweta Jaiswal, FRM
Moderna informs that the final-stage trial's primary aim will be to prevent the spread of coronavirus.
Top ETFs & Stocks From Top-Ranked Sectors
by Sweta Killa
Investors could be well served by ETFs and stocks from sectors that house top-ranked industries.